Advancing CAR-T therapy in multiple myeloma: a critical appraisal of CARTITUDE-4 and the path toward earlier lines - Top-Institutions - MDSpire

Advancing CAR-T therapy in multiple myeloma: a critical appraisal of CARTITUDE-4 and the path toward earlier lines

  • By

  • Chao-qun Zhou

  • Shi-Qiong Zhou

  • Qing-Hua Ke

  • May 26, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    University of Sydney
    University of Sydney

    Sydney, NSW

    Key Differentiators

    • Hematology

  • #2

    Royal Prince Alfred Hospital
    Royal Prince Alfred Hospital

    Sydney, NSW

    Key Differentiators

    • Hematology

  • #3

    National Cancer Institute
    National Cancer Institute

    Bethesda, MD

    Key Differentiators

    • Hematology
    • Oncology

  • #4

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Hematology
    • Oncology

Original Source(s)

Advancing CAR-T therapy in multiple myeloma: a critical appraisal of CARTITUDE-4 and the path toward earlier lines

  • by Chao-qun Zhou, Shi-Qiong Zhou, Qing-Hua Ke

  • May 26, 2026

Related Content

Subepithelial nevus and papilloma of the lacrimal caruncle: a case report and literature review

First-line penpulimab combined with anlotinib achieves complete response in an elderly patient with occult lung squamous cell carcinoma: a case report

Venetoclax combined with azacitidine in the treatment of secondary myelodysplastic syndrome following multiple myeloma: a case report and literature review